Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00547066 · ClinicalTrials.gov registry record · Phase 1
Study of Veltuzumab (hA20) at Different Doses in Patients With ITP
A Phase 1 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00547066: Clinical Trial Phase 1 study, sponsored by Gilead Sciences.
NCT00547066 is a Phase 1 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 48 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00547066, a Phase 1 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This trial will study different dose levels of hA20 (IMMU-106) to see if they are safe and effective for treating ITP.
Primary Outcome
Hematology laboratory results and adverse events will be followed closely for one year.
Interventions
- BIOLOGICAL veltuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2007-11 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Why NCT00547066 stopped before completion
NCT00547066 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 1 intervention - of which veltuzumab is the first listed.
NCT00547066 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00547066 about?
NCT00547066 is a clinical study titled "Study of Veltuzumab (hA20) at Different Doses in Patients With ITP". This trial will study different dose levels of hA20 (IMMU-106) to see if they are safe and effective for treating ITP.
What is the current status of trial NCT00547066?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2007-11. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00547066?
The interventions under investigation include: veltuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00547066?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00547066's enrollment target sits among peer trials
48 1025th of 2000 higher than 948 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia